Close

Orexigen Therapeutics (OREX) PT Trimmed at BofA/Merrill Lynch, But Bullish Stance Maintained

September 12, 2014 6:51 AM EDT
Get Alerts OREX Hot Sheet
Price: $0.22 --0%

Rating Summary:
    3 Buy, 7 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE

BofA/Merrill Lynch analyst Steve Byrne lowered his price target on Orexigen Therapeutics (NASDAQ: OREX) to $9.00 (from $10.00) following FDA approval of Contrave, which includes a new CVOT, but is sticking with his Buy rating on the stock.

Despite the CVOT and shorter discontinuation criterion, Byrne is positive on the stock due to strong US partner and several near-term catalysts, including EU approval (by year-end), ex-US partnership, and another interim analysis of the on-going CVOT study.

For an analyst ratings summary and ratings history on Orexigen Therapeutics click here. For more ratings news on Orexigen Therapeutics click here.

Shares of Orexigen Therapeutics closed at $5.28 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change, FDA